The novel candidate tumor suppressor p73, a structural and functional homolog of p53, activates various p53 responsive promoters and induces tumor cell apoptosis. Although p73 is infrequently mutated in human cancers, we have previously found two types of p73 mutation with amino acid substitution (P405R and P425L) in primary neuroblastoma and lung cancer. Here we report generations of the p73 mutants with either P405R or P425L substitution and functional analysis of these naturally occurring mutants. Indirect immuno¯uores-cence staining revealed that nuclear accumulation of p73a or p73b was not aected by these mutations. The P425L substitution reduced the ability of p73a to transactivate various p53 responsive promoters (p21 Waf1 , Mdm2, and Bax). Moreover, this down-regulation was correlated with the reduced capability of p73a(P425L) to suppress cell growth in p53-de®cient SAOS-2 cells. In contrast, p73b(P425L) was as eective as wild-type p73b in transactivation and growth inhibition. On the other hand, the P405R substitution had no signi®cant eect onIntroduction p73 is a newly identi®ed, structural as well as functional homolog of the tumor suppressor p53 (Kaghad et al., 1997; Dickman, 1997; Kaelin, 1999a, b; Ikawa et al., 1999) . It has been shown that, like p53, p73 can transactivate the endogenous target genes for p53 as well as the reporters containing p53-binding sites in p53-de®cient cells (Kaghad et al., 1997; Jost et al., 1997; Di Como et al., 1999) . Overexpression of p73 inhibits cell growth in the G1 phase of the cell cycle, or induces apoptosis (Kaghad et al., 1997; Jost et al., 1997) . Unlike p53, p73 encodes at least six alternative splicing variants (a, b, g, d, e , and x) with dierent COOH-terminal portions (Kaghad et al., 1997; De Laurenzi et al., 1998 : Ueda et al., 1999 De Laurenzi et al., 1999) . Additionally, the truncated p73 isoforms (DN-p73a and DN-p73b), which lacked the aminoterminal transactivation domain, have been discovered Pozniak et al., 2000) . They were generated from an alternative promoter present within the intron 3. Recently, we and others have found that both the sequence-speci®c DNA-binding activity and the transactivation function of p73a can be negatively regulated by its COOH-terminal region which shows no sequence similarity to that of p53 (Ueda et al., 1999; Ozaki et al., 1999) . Although extensive searches revealed that mutation in human cancers is infrequent in the coding region of p73 (Ikawa et al., 1999) , we found two missense mutations (P405R and P425L) which were located within the COOH-terminal glutamine-and proline-rich region of p73, in primary neuroblastoma and lung cancer Ikawa et al., 1999) . We previously demonstrated that this short glutamine and proline-rich segment (amino acid residues 382 ± 491) displayed a weak but signi®cant transactivation function in a GAL4 DNA-binding fusion system both in yeast and mammalian cells . Moreover, each of those mutations negatively aected the transactivation ability. However, it is still unclear whether or not a fulllength p73 protein carrying the P405R or the P425L mutation exhibits a reduced transcriptional activity and whether or not these mutations have an eect on the ability of p73 to suppress cell growth.
To characterize and examine a functional signi®-cance(s) of these naturally occurring missense mutations more precisely, we constructed expression plasmids encoding HA epitope-tagged mutant forms of p73, p73a(P405R), p73a(P425L), p73b(P405R), and p73b(425L) (Figure 1a ). These expression constructs along with those encoding p73 splicing variants, p73a, p73b or p73g, were translated in vitro in the presence of [ 35 S]methionine. As shown in Figure 1b , radio-labeled p73 derivatives of the expected sizes and comparable amounts were generated. To facilitate the detection of p73 derivatives in mammalian cells, we used human 293 cells with a high transfection eciency. Western blot analysis showed that stable fusion proteins with the expected sizes were recognized by a monoclonal anti-HA antibody (Figure 1c ). In addition, the distribution of the mutant p73 proteins as well as the p73 splicing variants was restricted to the nucleus (Figure 2 ), indicating that the nuclear localization of p73 was not in¯uenced by the P405R or P425L mutation. These results might be due to the fact that the P405R or P425L mutation occurred outside of the a b c Figure 1 Schematic representation of p73 splicing variants and mutants studied and their expression. (a) The NH 2 -terminal transactivation domain (TA; residues 1 ± 54) and the sequencespeci®c DNA-binding region (DB; residues 131 ± 310) are indicated by dotted boxes and gray boxes, respectively. The oligomerization domain (OD; residues 345 ± 380) and the SAM domain (SAM; residues 484 ± 549) are shown by hatched boxes. A unique pentamer speci®c for p73b and additional 76 amino acids found at the extreme COOH-terminus of p73g are depicted by ®lled boxes. Arrowheads indicate the positions of missense mutations. (b) Expression of mutant forms of p73a or p73b in vitro. Speci®c point mutations were introduced into the appropriate sites of p73a or p73b cDNA by using the PCRbased strategy. Each of mutant p73 cDNA was subcloned into the HindIII and NotI site of the pcDNA3 to give pcDNA3-p73a(P405R), pcDNA3-p73a(P425L), pcDNA3-p73b(P405R), or pcDNA3-p73b(425L). All plasmids were sequenced to con®rm that each of them carried the proper point mutation. Coupled transcription/translation was carried out with the TNT rabbit reticulocyte lysate system (Promega Corp.), according to the manufacturer's protocol. Brie¯y, wild-type and mutant forms of p73 constructs, which were cloned downstream of the T7 promoter in the pcDNA3 vector, were incubated for 90 min at 308C in the TNT lysate in the presence of [ 35 S]methionine (Amersham Pharmacia Biotech). The reaction mixtures were separated by 10% SDS ± PAGE. After electrophoresis, the gel was dried and exposed to an X-ray ®lm at room temperature. Molecular masses are shown in kDa (left). Arrowheads indicate the expected products. (c) 293 cells were transfected transiently with expression plasmids encoding indicated HA-tagged p73 proteins or with the empty vector (pcDNA3). Total cell lysates were separated by 10% SDS ± PAGE, and transferred to nitrocellulose membrane. The membrane was blocked with TBST [50 mM TrisCl (pH 7.6), 100 mM NaCl, and 0.1% Tween 20] containing 5% nonfat dry milk for 1 h at room temperature, and incubated with monoclonal anti-HA (12CA5) antibody (diluted 1 : 1000; Boehringer Mannheim Biochemicals) in TBST for 1 h, followed by incubation with a horseradish peroxidase-conjugated goat anti-mouse secondary antibody (diluted 1 : 4000; Jackson ImmunoResearch Laboratories). Molecular masses are shown in kDa (left). Arrowheads indicate the expected products Figure 2 Immuno¯uorescence staining of ectopically expressed mutant forms of p73. 293 cells were transfected transiently with 2 mg each of expression plasmid encoding HA-tagged p73a, p73a(P405R), p73a(P425L), p73b, p73b(P405R), p73b(P425L), or p73g. Forty-eight hours after transfection, cells were ®xed in freshly made 3.7% formaldehyde in PBS at room temperature for 30 min. The cells were then washed with PBS, permealized with PBS containing 0.1% Triton X-100 at room temperature for 5 min, and treated with blocking solution (3% BSA in PBS) at room temperature for 1 h to block nonspeci®c antibody-binding sites. The cells were incubated with monoclonal anti-HA (12CA5) antibody (diluted 1 : 100; Boehringer Mannheim Biochemicals). After washing three times with PBS, the cells were incubated with rhodamine-conjugated goat anti-mouse secondary antibody (diluted 1 : 200; Life Technologies, Inc.). Control transfection was carried out with pcDNA3
Oncogene Functional analysis of p73 mutants M Naka et al potential nuclear localization signal (338-PAL-GAGVKKRR-348) of p73 .
To assess eects of these mutations on p73 transactivation function, we examined the ability of p73 mutants to activate p53-responsive promoters in human p53-de®cient osteogenic sarcoma SAOS-2 cells. Equal amount of the expression plasmid encoding wild-type p53, p73a, p73b, p73g, p73a(P405R), p73a(P425L), p73b(P405R), or p73b(P425L) was transfected into SAOS-2 cells, along with a luciferase reporter plasmid containing a p53-responsive element derived from either human p21 Waf1 , Mdm2, or Bax promoter. As shown in Figure 3 , both the wild-type p53 and the p73 splicing variants (a, b, and g) transactivated all of three promoters to various degrees, which was basically consistent with that in the previous reports (Jost et al., 1997; De Laurenzi et al., 1998; Di Como et al., 1999; Ueda et al., 1999; Ozaki et al., 1999) . The Bax promoter was transactivated by p73a and p73b better than it was by wild-type p53. On the other hand, wild-type p53 was more ecient in activating transcription from the p21 Waf1 promoter than p73a and p73b were. As demonstrated previously, the ability of p73g to transactivate the p21 Waf1 promoter was weaker than that of p73b (De Laurenzi et al., 1998). The Bax promoter was transactivated by p73g at a level equivalent to p73a. In contrast, p73g could activate the Mdm2 promoter better than p73a. When the mutant form of p73a(P425L) was expressed in SAOS-2 cells, there occurred a signi®cant reduction (2 ± 3-fold) of the ability to activate the p53-responsive promoters compared with that of p73a. Thus, the structural alteration induced by the P425L mutation resulted in suppression of the p73a-mediated transcription activation. These observations suggested that the COOHterminal glutamine-and proline-rich region contributes to the regulation of the transactivation function of p73a. On the other hand, the ability of p73b to drive the Bax promoter was not aected by the P405R and P425L mutations. These two mutations reduced the activity of p73b to transactivate the p21 WAF1 and the MDM2 promoters, however, these inhibitory eects were less than twofold. Intriguingly, Di Como et al. (1999) reported that the transactivating function of p73a was inhibited by tumor-derived p53 mutants. Since p73 is rarely mutated in human cancers (Ikawa et al., 1999) , functional eects of tumor-derived p73 mutants on p53 have not been examined. We have preliminary indication that the transcriptional activity of p53 was not aected by p73a(P405R) or p73a(P425L) (data not shown).
The sequence-speci®c DNA-binding activity of p73a was not in¯uenced by the P425L mutation, as assayed a b c Figure 3 Transactivation activities of wild-type and mutant p73 proteins. SAOS-2 cells were cultured in Dulbecco's modi®ed Eagle's medium (DMEM) (Nissui) containing 10% fetal bovine serum (FBS), 50 units/ml penicillin and 50 mg/ml streptomycin at 5610 5 cells per 100 mm plate. Twenty-four hours after seeding, cells were transfected by the standard calcium phosphate/DNA precipitation procedure (Chen and Okayama, 1987) . Each transfection mixture contained one of the expression plasmids (as indicated in the ®gure) (10 mg of each) and two dierent reporter constructs, including 1 mg of a cytomegalovirus-derived Renilla luciferase cDNA and 9 mg of a ®re¯y luciferase reporter construct containing the p53-responsive element derived from p21 WAF1 (b), Mdm2 (b), or Bax (c). The cells were incubated for 24 h with the DNA before the transfection mixtures were replaced with fresh medium. The cells were harvested 48 h later and luciferase activity was determined by a dual-luciferase reporter gene assay system (Promega Corp.), according to the manufacturer's instructions. Fold activation is expressed relative to the empty vector. The data represent the average of three independent experiments Functional analysis of p73 mutants M Naka et al by the gel retardation experiments (data not shown). In contrast, the substitution of Pro of p73a (P405) with Arg showed no signi®cant eect on the transactivation function of p73a. Similarly, we could not detect signi®cant dierences between p73b and each of the p73b mutants [p73b(P405R) and p73b(P425L)] in the ability to transactivate all p53-responsive promoters. Takada et al. (1999) previously described that, in a GAL4 DNA-binding fusion system, the P405R mutation was as eective as the P425L mutation in inhibiting the transactivation activity detected within the COOH-terminal glutamine-and proline-rich region of p73a. As reported previously, an intramolecular interaction between the NH 2 -terminal domain or the central core DNA-binding region and the COOHterminal segment played an important role in p53 function (Friend, 1994; Anderson et al., 1997; Kim et al., 1999) . Similarly, the COOH-terminal region of p73a carries a regulatory role for its sequence-speci®c transactivation ability . Since the GAL4 DNA-binding fusion proteins used for the previous experiments lacked a possible intramolecular interaction of p73a, it was possible that the eect of the P405R mutation, if any, might be suppressed by an intramolecular interaction of p73a. In addition, p73b transactivation function was not aected signi®cantly by each of these missense mutations. According to the previous reports, the transactivation and the growthinhibitory activities of p73b were relatively higher than those of p73a (Jost et al., 1997; De Laurenzi et al., 1998; Fang et al., 1999; Ueda et al., 1999; Ozaki et al., 1999) . By comparison with the amino acid sequences between p73a and p73b, p73b is 137 amino acids shorter than p73a and possesses a unique pentamer at its extreme COOH terminus generated by an alternative splicing event. These observations along with the present data suggested the existence of an alternative regulatory mechanism for the p73b function. The eects of p73 mutations were examined in colony formation assays by transfecting SAOS-2 cells with the expression plasmids for each p73 derivative. pcDNA3 and the expression plasmid encoding wildtype p53 were used as a negative and a positive control, respectively. After G418 selection for 2 weeks, colonies that formed during this time were stained with Giemsa's solution, and numbers of drugresistant colonies were counted. As presented in Figure 4 , the number of G418-resistant colonies formed when transfected with wild-type p53, p73a, p73b, or p73g expression plasmid was reduced, as compared with cells that were transfected with the empty plasmid. Among the p73 splicing variants that were examined, p73b was the most ecient in inhibiting colony formation, as reported previously (De Laurenzi et al., 1998) . It is interesting to note that the missense mutation P425R of p73a resulted in an approximately twofold reduction of the capability of p73a to suppress cell growth. The substitution of Pro of p73a (P405) with Arg showed no signi®cant eect on the growth inhibitory activity of p73a. In addition, p73b(P405R) and p73b(P425L) were as eective as p73b in limiting cell growth. Recently, Laurenzi et al., (2000) have found that endogenous p73 level was elevated during neuroblastoma cell dierentiation and the ectopic overproduction of p73 induced the neuronal cell dierentiation. Alternatively, D-Np73 isoform, which lacks the aminoterminal transactivation domain, inhibited the proapoptotic function of wild-type p53 in neurons by hetero-oligomerization (Pozniak et al., 2000) . It will be interesting to investigate whether the p73 mutations can aect the neuronal cell dierentiation or the neuronal cell death. a b Figure 4 Colony formation assay. SAOS2 cells (5610 5 cells/ 100 mm plate) were transfected by the calcium phosphate/DNA precipitation procedure with 20 mg of the expression plasmid encoding wild-type p53 (b), p73g (c), p73a (d), p73a(P405R) (e), p73a(P425L) (f), p73b (g), p73b(P405R) (h), or p73b(P425L) (i). pcDNA3 was used for the control transfection (a). Stably transfected cells were selected with G418 for 2 weeks, and numbers of drug-resistant colonies were scored after staining with Giemsa's solution. (a) Results of one representative experiment of three independent assays are shown. (b) The numbers of G418-resistant colonies relative to that generated by the transfection with the control pcDNA3 plasmid are shown Using the transactivation and the standard colony formation assays, we have shown that one of the neuroblastoma-derived p73 mutations, P425L, signi®-cantly reduced both the sequence-speci®c transactivation ability and the growth-suppressive activity of p73a in p53-de®cient SAOS-2 cells, whereas p73b function was not aected by this P425L mutation. Furthermore, another mutation (P405R) detected in neuroblastoma and lung cancer was functionally silent. The vast majority of p53 mutations found in human tumors map within the sequence-speci®c DNA-binding domain (Hollstein et al., 1991; Ko and Prives, 1996) . In contrast to p53, the loss of function mutation (P425L) examined in this study was localized within the COOH-terminal extra sequence of p73a, suggesting an important role of this region in regulating not only the transactivation ability but also the growthinhibitory function of p73a.
Recently, Zeng et al. (1999) reported that Mdm2 inhibited the interaction between p73 and p300 coactivator protein and repressed the p73 function. In addition, the p73-mediated transactivation and apoptosis-inducing activities were regulated by the functional interaction of p73 with the nuclear tyrosine kinase, c-Abl (Gong et al., 1999; Agami et al., 1999; Yuan et al., 1999) . These results strongly suggest that protein-protein interactions play an important role in the regulation of p73. Therefore, the identi®cation of p73-binding protein(s) whose interaction is interrupted by the P425L mutation may be necessary to uncover the p73-mediated cellular response. In that connection, the yeast-based two-hybrid screening is currently in progress in our laboratory.
